Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics

Seelos Therapeutics, Inc. (SEEL): $0.35

0.01 (+3.11%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add SEEL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#173 of 361

in industry

SEEL Price/Volume Stats

Current price $0.35 52-week high $49.80
Prev. close $0.34 52-week low $0.32
Day low $0.33 Volume 240,062
Day high $0.36 Avg. volume 430,766
50-day MA $0.77 Dividend yield N/A
200-day MA $11.75 Market Cap 4.77M

SEEL Stock Price Chart Interactive Chart >


Seelos Therapeutics, Inc. (SEEL) Company Bio


Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.


SEEL Latest News Stream


Event/Time News Detail
Loading, please wait...

SEEL Latest Social Stream


Loading social stream, please wait...

View Full SEEL Social Stream

Latest SEEL News From Around the Web

Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.

Seelos Therapeutics, Inc. Releases Letter to its Stockholders

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below.

Yahoo | December 22, 2023

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

Insider Spends US$100k Buying More Shares In Seelos Therapeutics

Investors who take an interest in Seelos Therapeutics, Inc. ( NASDAQ:SEEL ) should definitely note that the Chief...

Yahoo | December 4, 2023

Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)

In the realm of stock market movements, insider trading can provide valuable insights into a company's health and future prospects.

Yahoo | December 2, 2023

Seelos Therapeutics Announces Closing of Public Offering

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. Each share of comm

Yahoo | December 1, 2023

Read More 'SEEL' Stories Here

SEEL Price Returns

1-mo -36.13%
3-mo -72.44%
6-mo -94.09%
1-year -98.43%
3-year -99.77%
5-year -99.60%
YTD -74.82%
2023 -93.18%
2022 -58.34%
2021 3.16%
2020 17.91%
2019 -76.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!